Recent developments highlight ongoing clinical trial progress, updates to enrollment criteria, and continued reporting of quarterly financial results with net losses and limited revenue.

• Aclarion updated enrollment criteria for its CLARITY clinical trial to maintain the trial timeline [N5].
• The company reported a Q2 2026 net loss and revenue below expectations, reflecting early commercialization challenges [N6].
• Aclarion reported a Q1 2026 net loss and missed revenue expectations [N8].

The company has demonstrated clinical validation of its NOCISCAN technology with durable patient outcomes and has secured CPT codes facilitating reimbursement. Expansion of commercial agreements with leading medical institutions and progress in clinical trials like CLARITY support commercialization efforts. The integration of AI and machine learning to enhance diagnostic accuracy and potential expansion into neck pain and other clinical areas could broaden market opportunities. Strong liquidity provides operational runway to advance product development and market penetration.

Aclarion faces challenges including limited current sales, ongoing net losses, and minimal revenue, reflecting early-stage commercialization. The technology's dependence on compatibility with specific MRI scanner models limits market reach. Clinical adoption may be slow due to entrenched diagnostic standards and the invasive nature of alternative tests. Regulatory and reimbursement pathways remain complex, and there is risk that AI development and broader clinical applications may not achieve anticipated utility. Market competition and technological advances by others could impact future prospects.

Aclarion's moat derives from its proprietary MRS-based technology and biomarkers exclusively licensed from UCSF, supported by a robust patent portfolio including U.S. and foreign patents. The clinical evidence published in peer-reviewed journals and the receipt of CPT codes for reimbursement provide regulatory and commercial barriers to entry. The company's early mover advantage in applying AI and machine learning to MRS data for spine pain diagnostics further strengthens its competitive position. However, the technology's compatibility limitations with MRI scanners and the need for broader adoption in clinical practice present challenges to moat expansion.

• Commercialization Risk: Limited sales to date and early-stage commercialization may delay revenue growth and market adoption.
• Technology Compatibility: NOCISCAN is currently compatible with a limited number of MRI scanner models, restricting potential market penetration.
• Clinical Adoption: Physician acceptance and integration into standard care protocols may be slow due to existing diagnostic practices and patient preferences.
• Regulatory and Reimbursement: Securing and maintaining insurance reimbursement through CPT codes and payer acceptance involves ongoing regulatory risk.
• Financial Risk: The company reports ongoing net losses and minimal revenue, requiring sufficient liquidity to sustain operations and development.

• Aclarion, Inc. is a healthcare technology company leveraging Magnetic Resonance Spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments, focusing on the U.S. low back and neck pain market valued at $134.5 billion as of 2020 [S1].
• The company uses Artificial Intelligence (AI) to assist in quality control of spectroscopy data and aims to develop machine learning algorithms associating MRS data with clinical outcomes [S1].
• Aclarion's initial commercial product, NOCISCAN®, uses MRS data and proprietary algorithms to identify intervertebral discs consistent with pain to assist surgical decision-making for chronic discogenic low back pain (DLBP) patients [S1].
• Clinical studies published in the European Spine Journal (2019 and 2023) show improved surgical outcomes when discs identified as painful by NOCISCAN are treated, with 85-97% of patients meeting clinical improvement criteria [S1].
• The company holds a patent portfolio including 28 U.S. patents, 24 foreign patents, and multiple pending applications, some exclusively licensed from the University of California [S1].
• NOCISCAN technology received four Category III CPT codes effective January 1, 2021, facilitating insurance reimbursement efforts [S1].
• Aclarion is conducting the CLARITY clinical trial evaluating NOCISCAN in spine surgery and has updated enrollment criteria to maintain trial timelines [N5].
• The company has commercial agreements expanding NOCISCAN access at multiple clinical sites, including Weill Cornell, University of Miami, Texas Back Institute, Spine Institute of Louisiana, and Scripps Health [N5, N15, N19, N22, N23].
• Aclarion's technology is compatible with certain Siemens MRI scanners and has begun engagements with Philips MRI systems to expand compatibility [S1].
• The company reported a net loss of $2.62 million and revenue of $33,733 for the quarter ended September 30, 2026, with a cash balance of approximately $14.2 million and a strong liquidity position (current ratio 14.17, cash ratio 13.79) [S2].
• Recent quarterly reports indicate ongoing losses and revenue below expectations, reflecting early commercialization and development stage [N6, N8].